Editorial companion

What stands out

Bloomberg’s Stock Movers captured a tidy market split: Novartis plunged as much as 10% after its third clinical-trial setback in a week, a late-stage failure in a rare muscle-wasting disease that cut its year-to-date gain to roughly 4% versus Roche, while Computacenter jumped about 7.4% to a record high after again raising profit-before-tax guidance for fiscal year 2026 (FY2026) thanks to heavy artificial intelligence (AI), related spending, and Rubis advanced roughly 5.3% after lifting EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) guidance. The clip is useful because it compresses two lessons: drug development is binary and headline-driven, whereas repeatable guidance upgrades tied to durable demand get rewarded. For active investors this is a reminder to treat different kinds of “good news” and “bad news” with different sizing and skepticism.